Last modified: 03 November 2011

Funding Policy: Supporting Members

Patient organization-commercial company partnerships are sometimes viewed with scepticism by decision-makers and the general public. Some believe that pharmaceutical companies coerce patient organizations into conforming to their marketing agenda. In order to protect the Network's reputation and demonstrate that Myeloma Euronet does not conform to commercial agendas, the Network has adopted a detailed Funding Policy.

2011

Myeloma Euronet is supported by an unrestricted grant from Amgen Inc.
Myeloma Euronet is supported by an unrestricted grant from Celgene GmbH.
Myeloma Euronet is supported by an unrestricted grant from Celgene International Sàrl.
Myeloma Euronet is supported by an unrestricted grant from Ortho Biotech, Biopharmaceutical Division of Janssen-Cilag.
Myeloma Euronet is supported by an unrestricted grant from Novartis Pharma AG.

2010

Myeloma Euronet is supported by an unrestricted grant from Amgen Inc.
Myeloma Euronet is supported by an unrestricted grant from Celgene GmbH.
Myeloma Euronet is supported by an unrestricted grant from Celgene International Sàrl.
Myeloma Euronet is supported by an unrestricted grant from Ortho Biotech, Biopharmaceutical Division of Janssen-Cilag.
Myeloma Euronet is supported by an unrestricted grant from Novartis Pharma AG.
Myeloma Euronet is supported by an unrestricted grant from Roche AG.

2009

Myeloma Euronet is supported by an unrestricted grant from Amgen Inc.
Myeloma Euronet is supported by an unrestricted grant from Celgene GmbH.
Myeloma Euronet is supported by an unrestricted grant from Celgene International Sàrl.
Myeloma Euronet is supported by an unrestricted grant from Janssen-Cilag GmbH.
Myeloma Euronet is supported by an unrestricted grant from Novartis Pharma AG.
Myeloma Euronet is supported by an unrestricted grant from Ortho Biotech – A division of Janssen-Cilag AG.
Myeloma Euronet is supported by an unrestricted grant from Ortho Biotech, Biopharmaceutical Division of Janssen-Cilag.
Myeloma Euronet is supported by an unrestricted grant from Roche AG.

2008

Myeloma Euronet is supported by an unrestricted grant from Celgene GmbH.
Myeloma Euronet is supported by an unrestricted grant from Celgene International Sàrl.
Myeloma Euronet is supported by an unrestricted grant from Novartis Pharma AG.
Myeloma Euronet is supported by an unrestricted grant from Ortho Biotech, Biopharmaceutical Division of Janssen-Cilag.
Myeloma Euronet is supported by an unrestricted grant from Pharmion Ltd.
Myeloma Euronet is supported by an unrestricted grant from Roche AG.

2007

Myeloma Euronet is supported by an unrestricted grant from Amgen Inc.
Myeloma Euronet is supported by an unrestricted grant from Celgene GmbH.
Myeloma Euronet is supported by an unrestricted grant from Celgene International Sàrl.
Myeloma Euronet is supported by an unrestricted grant from Novartis Pharma AG.
Myeloma Euronet is supported by an unrestricted grant from Ortho Biotech, Biopharmaceutical Division of Janssen-Cilag.
Myeloma Euronet is supported by an unrestricted grant from Pharmion Ltd.
Myeloma Euronet is supported by an unrestricted grant from Roche AG.
Myeloma Euronet is supported by an unrestricted grant from The Steel Charitable Trust.

2006

The Portuguese translation of this Web site was made possible through a restricted grant from Amgen Inc.
Myeloma Euronet is supported by an unrestricted grant from Novartis Pharma AG.
Myeloma Euronet is supported by an unrestricted grant from Ortho Biotech, Biopharmaceutical Division of Janssen-Cilag.
Myeloma Euronet is supported by an unrestricted grant from Pharmion Ltd.
Myeloma Euronet is supported by an unrestricted grant from Roche AG.

2005

Ortho Biotech, Biopharmaceutical Division of Janssen-Cilag, is the founding sponsor of Myeloma Euronet.
Myeloma Euronet is supported by an unrestricted grant from Ortho Biotech, Biopharmaceutical Division of Janssen-Cilag.
Myeloma Euronet is supported by an unrestricted grant from Novartis Pharma AG.